ANI Pharmaceuticals is an integrated specialty pharmaceutical company focused on delivering value to
our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. We focus on niche and high barrier to entry opportunities including controlled substances,
anti-cancer (oncolytics), hormones and steroids, and complex formulations. Our two pharmaceutical manufacturing facilities located in Baudette, Minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. Our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize Cortrophin gel and Cortrophin-Zinc.
our customers by developing, manufacturing, and marketing high quality branded and generic prescription pharmaceuticals. We focus on niche and high barrier to entry opportunities including controlled substances,
anti-cancer (oncolytics), hormones and steroids, and complex formulations. Our two pharmaceutical manufacturing facilities located in Baudette, Minnesota are capable of producing oral solid dose products, as well as liquids and topicals, controlled substances, and potent products that must be manufactured in a fully-contained environment. Our objective is to create long term shareholder value by building a sustainable and growing base business in generic and mature brand pharmaceutical products while advancing an opportunity to re-commercialize Cortrophin gel and Cortrophin-Zinc.
Location: United States, Minnesota, Baudette
Employees: 201-500
Founded date: 1996
Investors 1
| Date | Name | Website |
| - | The Argent... | argentumgr... |
Mentions in press and media 7
| Date | Title | Description |
| 20.08.2024 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, ALIM, INFN on Behalf of Shareholders | NEW YORK, Aug. 20, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders rela... |
| 13.08.2024 | ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers’ Option to Purchase Additional Notes | PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the closing of its offering of $316,250,000 aggregate principal amount of 2.25% convertible senior notes due 20... |
| 13.08.2024 | ANI Pharmaceuticals, Inc. Closes $316.25 Million Convertible Senior Notes Offering Including Full Exercise of Initial Purchasers’ Option to Purchase Additional Notes | PRINCETON, N.J., Aug. 13, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (ANI or the Company) (Nasdaq: ANIP) today announced the closing of its offering of $316,250,000 aggregate principal amount of 2.25% convertible senior notes due 20... |
| 31.07.2024 | Calliditas Therapeutics: Navigating Shareholder Waters Amidst Corporate Changes | In the world of finance, numbers tell stories. They pulse with the rhythm of market dynamics, reflecting the health of companies and the sentiments of investors. Calliditas Therapeutics AB, a biopharmaceutical company based in Stockholm, re... |
| 26.07.2024 | SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALIM, DOMA, CALT on Behalf of Shareholders | NEW YORK, July 26, 2024 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders rela... |
| 01.06.2020 | ANI PHARMACEUTICALS, INC. ANI Pharmaceuticals : Provides Update on Recent Regulatory Filing | BAUDETTE, Minn., June 1, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (NASDAQ: ANIP) announced today that it continues to make progress toward addressing items identified in the Refusal to File letter received from the F... |
| - | Building a diversified biopharma company across rare disease, branded, and generics to serve patients in need | For the employees of ANI, it’s personal. We strive to make the lives of patients better as a result of the work we do every day. I have seen the debilitating impact of disease in my own family and knowing that ANI can play a role in allevia... |